- Anniversary/History
- Membership
- Publications
- Resources
- Education
- Events
- Outreach
- Careers
- About
- For Pain Patients and Professionals
Currently available treatments for neuropathic pain are only modestly efficacious when assessed in randomized clinical trials and only work for some patients in the clinic. Induced-pain or gain-of-function phenotypes, have been shown to predict response to analgesics (vs. placebos) in patients with neuropathic pain. However, the predictive value of these phenotypes has never been studied in post-traumatic neuropathic pain. Mixed-effects model for repeated measures (MMRM) were used to evaluate the efficacy of pregabalin vs. placebo in subgroups with induced-pain phenotypes (i.e., hyperalgesia or allodynia) using data from a recent, multi-national RCT (N = 539) that identified phenotypic subgroups using a structured clinical exam. The difference in mean pain score between active and placebo groups (i.e., delta) after 15 weeks of treatment for the subgroup with hyperalgesia was -0.76 (p = 0.001), compared to 0.19 (p = 0.47) for the subgroup that did not have hyperalgesia. The treatment-by-phenotype interaction, which tests whether subgroups have statistically different treatment responses, was significant (p = 0.0067). The delta for the subgroup with allodynia was -0.31 (p = 0.22), compared to -0.30 (p = 0.22) for the subgroup that did not have allodynia (treatment-by-phenotype interaction p = 0.98). These data suggest that hyperalgesia, but not allodynia predicts response to pregabalin in patients with chronic post-traumatic neuropathic pain. This study extends the growing data supporting the utility of induced-pain phenotypes to predict response to analgesics to post-traumatic neuropathic pain. Sensory phenotyping in large, multi-site trials using a structured clinical exam has the potential to accelerate the development of new analgesics and improve the generalizability of clinical trial results.